Overview

A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Participants with Chronic Hepatitis C (CHC) and normal ALT, who have been under treatment with peginterferon alfa-2a and ribavirin for at least 4 weeks, will be enrolled into this non-interventional, open-label study. The primary aim is to evaluate quality of life according to the 36-Item Short-Form Health Survey (SF-36) questionnaire, modified for the Greek population.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Interferon-alpha
Peginterferon alfa-2a
Ribavirin